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Summary 
The binding site of the dopamine D2 receptor, like that 
of other homologous G protein-coupled receptors, is 
contained within a water-accessible crevice formed 
among its seven membrane-spanning segments. We 
have developed a method to map systematically all 
the residues forming the surface of this binding-site 
crevice, and we have applied this method to the third 
membrane-spanning segment (M3). We mutated, one 
at a time, 23 residues in and flanking M3 to cysteine 
and expressed the mutant receptors heterologously. 
Ten of these mutants reacted with charged, hydro- 
philic, lipophobic, sulfhydryl-specific reagents, added 
extracellularly, and were protected from reaction by a 
reversible dopamine antagonist. Thus, the side chains 
of these residues are exposed in the binding-site crev- 
ice, which like M3 extends from the extracellular to 
the intracellular side of the membrane. The pattern of 
exposure is consistent with a short loop followed by 
six turns of an a helix. 
Introduction 
The dopamine receptors, like the homologous receptors 
for the biogenic amines and for acetylcholine, bind neuro- 
transmitters present in the extracellular medium and cou- 
ple this binding to the activation of intracellular G proteins 
(Civelli et al., 1991; Strader et al., 1994). The binding sites 
of these receptors are formed among their seven, mostly 
hydrophobic, membrane-spanning segments (Oprian, 
1992; Strader et al., 1994) and are accessible to charged, 
water-soluble agonists like dopamine. Thus, each of these 
binding sites is contained within a water-accessible crev- 
ice, the binding-site crevice, extending from the extracellu- 
lar surface of the receptor into the plane of the membrane. 
The surface of this crevice is formed by residues that con- 
tact specific agonists and/or antagonists and other resi- 
dues that may affect binding indirectly. 
To identify the residues that form the surface of the bind- 
ing-site crevice in the human D2 receptor, we have 
adapted a new approach, the substituted-cysteine acces- 
sibility method (SCAM; Akabas et al., 1992, 1994a). Con- 
secutive residues in the membrane-spanning segments 
are mutated to cysteine, one at a time, and the mutant 
receptors are expressed in heterologous cells. The sur- 
face exposure of a cysteine is inferred from the irreversible 
effects of sulfhydryl-specific reagents on binding. There- 
fore, the method requires that binding still be measurable 
after the mutation to cysteine. In ligand-gated ion chan- 
nels, the substitution by cysteine of individual residues in 
channel-forming membrane-spanning segments was very 
well tolerated (Akabas et al., 1992, 1994a, 1994b; Xu and 
Akabas, 1993). If ligand binding to a cysteine-substitution 
mutant is near normal, it is likely that the structure of the 
mutant receptor is similar to that of wild type and that the 
substituted cysteine lies in a similar orientation to that of 
the wild-type residue. 
In the membrane-spanning segments, the sulfhydryl of 
a cysteine can face either into the binding-site crevice, 
into the interior of the protein, or into the lipid bilayer; only 
sulfhydryls facing into the binding-site crevice should be 
accessible to hydrophilic, lipophobic, sulfhydryl-specific 
reagents (Figure 1). For such reagents, we use derivatives 
of methanethiosulfonate (MTS): positively charged MTS 
ethylammonium (MTSEA) and MTS ethyltrimethylammon- 
ium (MTSET), and negatively charged MTS ethylsulfonate 
(MTSES; Stauffer and Karlin, 1994). These reagents are 
about the same size as dopamine, with maximum dimen- 
sions of about 10 ,~, by 6 ~,. They form mixed disulfides 
with the cysteine sulfhydryl, covalently linking -SCH2CH2X, 
where X is NH3 +, N(CH3)3 +, or SO3-. 
We use two criteria for identifying an engineered cys- 
teine as being in the binding-site crevice: first, the reaction 
with an MTS reagent alters binding irreversibly (Figure 
1); second, this reaction is retarded by the presence of 
agonists or antagonists, A related approach has been 
used to identify residues lining the channels of the nicotinic 
acetylcholine receptor (Akabas et al., 1992, 1994a), the 
y-aminobutyric acid type A receptor (Xu and Akabas, 
1993), and the cystic fibrosis transmembrane conduc- 
tance regulator (Akabas et al., 1994b). Covalent modifica- 
tion of substituted cysteines has also been used to study 
the structures of a number of bacterial membrane proteins 
(Falke et al., 1988; Todd et al., 1989; Altenbach et al., 
1990; Jakes et al., 1990; Pakula and Simon, 1992; Jung 
et al., 1993). 
We previously found that antagonist binding to wild-type 
D2 receptor is irreversibly inhibited by MTSEA and MTSET 
and that Cys-118, in the third membrane-spanning seg- 
ment (M3), is responsible for this sensitivity (Javitch et 
al., 1994). We therefore used the mutant Cl18S, which 
is insensitive to MTS reagents, as the starting point for 
further mutation. Because we already identified one resi- 
due in M3 (Cys-118) as being exposed in the binding-site 
crevice and because another (Asp-114) also likely faces 
the crevice (Mansour et al., 1992), we applied SCAM first 
to M3. 
In the 13-adrenergic receptor, residues that contribute 
to binding have been identified in membrane-spanning 
segments M3, M5, M6, and M7: mutations of Asp-113, 
Ser-204, Ser-207, and Phe-290 altered binding (Strader 
et al., 1994); and Trp-330 was affinity-labeled by an antag- 
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Figure 1. Schematic Representation of the Reaction of the MTS Re- 
agents with a Cysteine Exposed in the Binding-Site Crevice 
The membrane is represented by a stippled rectangle, the binding-site 
crevice is indicated within the plane of the membrane, and the solid 
oval represents ligand. SEX represents -SCH2CH2X (where X is NH3 ÷, 
N(CH3)3 ÷, or SOz ), which is covalently linked to the water-accessible 
cysteine sulfhydryl. In the bound state (top), ligand is reversibly bound 
at the binding site within the binding-site crevice. In the unbound state 
(middle), the binding site is unoccupied. After irreversible reaction with 
MTSEX (bottom), ligand can no longer bind. The cysteine sulfhydryl- 
facing lipid or the interior of the protein does not react with MTSEX. 
MTSEX can react only with a sulfhydryl in the binding-site crevice of 
unbound receptor and not of bound receptor. Thus, ligand retards the 
rate of reaction of receptor with MTSEX, thereby protecting subse- 
quent ligand binding. 
onist derivative (Wong et al., 1988). These 5 residues are 
identically conserved in all catecholamine receptors. In 
the dopamine D2 receptor, mutation of the residues that 
align with the first 3 above (Asp-114, Ser-194, and Ser-197) 
also altered the binding of dopamine agonists and antago- 
nists (Cox et al., 1992; Mansour et al., 1992). Completely 
conserved residues, however, cannot account for the pro- 
found differences in binding specificities among the cate- 
cholamine receptors. Additional residues must contribute 
to binding, either directly or indirectly. All the residues that 
contact ligand must be among those residues that form 
the surface of the binding-site crevice. 
Results 
Effects of Cysteine Substitution on 
Antagonist Binding 
Starting with C 118S, we mutated to cysteine, one at a time, 
residues Asp-108 to Ile-130, in and flanking M3. (Note that 
M3 contains another cysteine, Cys-126, which is insensi- 
tive to the MTS reagents; Cys-126 is present in C l18S 
and in all further mutants.) Each mutant receptor was tran- 
siently expressed in HEK 293 cells, and the Ka and Bin=, 
characterizing the equilibrium binding of the radiolabeled 
antagonist, [3H]YM-09151-2, were determined, At 22 posi- 
tions, cysteine substitution had at most moderate effects 
on the binding of [3H]YM-09151-2: affinities of the mutants 
for [3H]YM-09151-2 were at most decreased 5-fold from 
that of C118S, and the maximal number of binding sites 
ranged from 35% to 100% of that obtained with C l18S  
(Table 1). Only the mutant D l14C failed to bind [3H]YM- 
09151-2. 
Reactions of the Mutants with MTSEA 
Based on irreversible inhibition of binding, we infer that 
MTSEA reacted with cysteines at 11 of 22 positions tested 
(Figure 2A). The reversible antagonist sulpiride (10 I~M) 
retarded the reaction of MTSEA with each of the reactive 
mutants (Figure 3). Based on our criteria and on the as- 
sumption that the cysteine side chains are in the same 
position as the wild-type side chains, the side chains of 
the following 10 residues are exposed in the binding-site 
crevice: Asp-108, Ile-109, Phe-110, Val-111, Val-115, Cys- 
118, Ser-121, Ile-122, Leu-125, and Ser-129. (The effect of 
MTSEA on N 124C was too sm all to test sulpiride protection 
reliably.) 
Table 1. Characteristics of [ZH]YM-09151-2 Binding to 
Cysteine-Substituted Dopamine D2 Receptor 
Bnax 
Ko (pM) (fmol/cm 2) n 
WT 16 ± 2 131 ± 27 4 
Cl18S 29 ± 3 99 ± 29 4 
Cl18S + 
D108C 106 ± 5 45 ± 5 3 
1109C 38 ± 6 45 ± 8 5 
F110C 50 ± 8 67 ± 8 4 
Vl11C 35 ± 2 96 ± 5 4 
Tl12C 35 ± 2 99 ± 16 2 
Ll13C 100 ± 19 104 ± 24 3 
Dl14C No binding dete~ed 3 
Vl15C 153 ± 18 107 ± 3 4 
Ml16C 40 ± 0 115 ± 21 2 
Ml17C 44 ± 7 99 ± 27 2 
WT (Cl18) 16 ± 2 131 ± 27 4 
Tl19C 77 ± 3 61 ± 5 2 
A120C 21 ± 3 64 ± 5 2 
$121C 100 ± 24 35 ± 8 4 
1122C 18 ± 1 93 ± 27 4 
L123C 38 ± 2 48 ± 11 2 
N124C 35 ± 9 56 ± 11 3 
L125C 58 ± 11 104 ± 24 3 
C126 29 ± 3 99 ± 29 4 
A127C 32 ± 6 85 ± 3 3 
1128C 36 ± 1 85 ± 3 3 
$129C 65 ± 5 67 ± 3 3 
1130C 22 ± 2 61 ± 5 3 
Cells transiently transfected with the appropriate receptor were incu- 
bated with six different concentrations of [3H]YM-09151-2 between 5 
and 400 pM and assayed as described in Experimental Procedures. 
Data were fit to the binding isotherm by nonlinear regression. The 
means and SEM are shown for n independent experiments, each with 
triplicate determinations. Bm~ values are presented as femtomoles per 
square centimeter of plate area. Note that C118S is the same as C 126. 
WT, wild type. 
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Figure 2. The Inhibition of Specific [3H]YM- 
09151-2 Binding to Wild-Type or Mutant D2 Re- 
ceptors Resulting from Application of MTSEA 
MTSEA was applied for 2 min at a concentra- 
tion of either 2.5 mM (A) or 0.25 mM (B) to intact 
cells transiently transfected with wild-type or 
mutant D2 receptors and incubated with 100 
pM [3]YM-09151-2. The means and SEM are 
shown. The number of independent experi- 
ments for each mutant is shown next to the 
bars. Closed bars indicate mutants for which 
inhibition was significantly different (p < .05) 
than Cl18S by one-way ANOVA. In Cl18S, 
Cys-126 is the only cysteine present in M3, but 
it is insensitive to the MTS reagents. Cys-126 
is thus present in all the mutants. WT, wild type, 
asterisk, no detectable binding. 
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Figure 3. Sulpiride Protection of Cysteine-Substitution Mutants 
Dissociated cells were incubated in buffer B for 20 min at room temper- 
ature in the presence or absence of 10 p.M sulpiride, and then MTSEA 
was added, in the continued presence or absence of sulpiride, for 2 
min at a concentration chosen to inhibit 50%-75% of specific [3H]YM- 
09151-2 binding in the absence of sulpiride. Concentrations of MTSEA 
were as follows: 2.5 mM: L125C and $129C; 1 raM: D108C, 1109C, 
F110C, and 1122C; 0.25 mM: Vl 11 C, Cys-118, and $121C; 0.025 mM: 
Vl15C. Cells were washed by filtration though 96-well multiscreen 
plates containing GFB filters (Millipore). In the wash buffer, sodium was 
replaced by choline to facilitate removal of residual sulpiride (Jarvie et 
al., 1987). Binding of [3H]YM-09151-2 to the washed cells was per- 
formed in buffer B in the multiscreen plates in a final volume of 0.25 
ml. The means and SEM of three to nine independent experiments, 
each performed with triplicate determinations, are shown. Closed bars, 
inhibition by MTSEA alone; hatched bars, inhibition by MTSEA in the 
presence of sulpiride. In each mutant, protection by sulpiride was sig- 
nificant (p < .05) by paired t test. 
Some subst ituted cysteines were markedly  more sensi- 
tive to MTSEA than others (Figure 2B). To quantitate this, 
we determined the second-order  rate constant  for the de- 
crease in binding (Table 2). The most reactive cysteines 
are Cys-118 and those substituted for Val-111 and Vai- 
l 15. In a helical-net representat ion,  these 3 residues clus- 
ter around Asp-114 (Figure 4A). Cysteines substituted for 
Ser-121 and Ile-122, located closer to the cytoplasmic side 
than the highly reactive Cys-118, were  of intermediate re- 
activity with MTSEA.  Cysteines substituted for the 3 most  
extracel lular,  susceptible residues and the 3 most cyto- 
plasmic, susceptible residues were  the least reactive. Sur- 
prisingly, Leu-125 and Ser-129, putatively at the cyto- 
plasmic end of M3 (Probst et al., 1992; Baldwin, 1993), 
were  accessible to MTSEA.  
Table 2. Rates of Reaction of MTSEA with Cysteine-Substituted 
Dopamine D2 receptor 
KMTSEA 
(M-is -') K,,=/K~r 
Cl18S+ 
D108C 9.0 4. 1.0 0.22 
1109C 8.0 4. 0.0 0.21 
F110C 8.0 4. 0.0 0.21 
V111C 23.0 4. 1.0 0.58 
V115C 167.0 4. 0.0 4.3 
Wf(C118) 39.0 4. 6.0 1.0 
$121C 15.0 ± 1.0 0.39 
1122C 11.0 4. 1.0 0.28 
N124C 2.0 4. 0.0 0.05 
L125C 5.0 4. 0.0 0.12 
$129C 4.0 4. 1.0 0.10 
The second-order ate constant (k) for each susceptible mutant was 
quantitated by incubating intact cells with four concentrations of 
MTSEA between 0.01 and 2.5 m M (all in great excess over the quantity 
of reactive sulfhydryls) for 2 rain. The extent of reaction was taken to 
be proportional to the extent of inhibition of binding, which followed 
pseudo-first-order kinetics as a function of MTSEA concentration. The 
pseudo-first-order rate constant was divided by 120 s to obtain the 
second-order rate constant. The means and SEM of two independent 
experiments, each performed with triplicate determinations, are 
shown. K~,t/kwT was obtained by dividing each k value by the k deter- 
mined for the wild-type receptor in which Cys-118 reacts. Note that 
Cl18S is the same as C126. WT, wild type. 
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Figure 4. Helical-Net and Helical-Wheel Rep- 
resentations of the Residues in and Flanking 
the M3 Segment of the Dopamine D2 Receptor 
The helical-net (A) and helical-wheel (B) repre- 
sentations summarize the effects of MTSEA on 
[3H]YM-09151-2 binding. Reactive residues are 
represented by squares, where the fill indicates 
the range of the second-order rate constants 
(M-~s -1) for reaction with MTSEA (see Table 2): 
closed squares, k > 20; cross-hatched squares, 
15 > k > 10; striped squares, 9 > k > 4; open 
squares, 2 > k > 1. Open circles indicate that 
MTSEA had no effect on binding. Closed circle 
indicates no binding after cysteine substitution. 
The arrow indicates where the helix is split to 
create the helical net. D108 and 1109 are repre- 
sented outside of the a helix (see Discussion). 
Reactions with MTSET and MTSES 
Of the residues that reacted with MTSEA, MTSET reacted 
with cysteines substituted only for Asp-108, Ile-109, Phe- 
110, Val-111, Va1-115, Cys-118, Ser-121, and no others 
(Figure 5A). At these residues, 2 rain of 1 mM MTSET 
inhibited binding only as much as 2 rain of 0.25 mM 
MTSEA, despite the 2.5-fold higher reactivity of MTSET 
compared with MTSEA with sire pie thiols in solution (Stauf- 
fer and Karlin, 1994); i.e., MTSET reacts slower than 
MTSEA in the binding-site crevice. 
MTSES, the negatively charged derivative, although 
slightly smaller than MTSET, reacted only with residues 
substituted for Asp-108, Ile-109, Phe-110, and Val-111, at 
the extracellular end of M3 (Figure 5B). MTSES decreased 
binding to 1109C, F110C, and V111C but increased bind- 
ing to D108C, where it restored the original negative 
charge. 
Discussion 
Residues Exposed in the Binding-Site Crevice 
We used SCAM to identify residues exposed in the bind- 
ing-site crevice. We make the following assumptions. The 
highly polar MTS reagents (Stauffer and Karlin, 1994) re- 
act only at the water-accessible surface of the protein. In 
the membrane-spanning segments, access of highly polar 
reagents to side chains is only through the binding-site 
crevice. The addition of -SCH2CH2X to a cysteine at the 
surface of the binding-site crevice alters binding irrevers- 
ibly, and, reciprocally, competitive antagonists and ago- 
nists should retard the reaction with MTSEX. Based on 
these assumptions, on the irreversible inhibition of binding 
by MTSEA, and on the retardation of this reaction by sulpir- 
ide, we infer that 10 of the 22 residues tested are exposed 
in the binding-site crevice: Asp-108, Ile-109, Phe-110, Val- 
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Figure 5. The Inhibition of Specific [3H]YM- 
09151-2 Binding to Wild-Type or Mutant D2 Re- 
ceptors Resulting from Application of MTSET 
or MTSES 
MTSET (A) or MTSES (B) was applied for 2 
min to intact cells transiently transfected with 
wild-type or mutant D2 receptors and incu- 
bated with 100 pM [3H]YM-09151-2. Based on 
the relative rate constants for reaction with sim- 
ple thiols in solution (10:4:1 for MTSET, 
MTSEA, and MTSES, respectively; Stauffer 
and Karlin, 1994), we used equireactive con- 
centrations of 1 mM MTSET (A), 2.5 mM 
MTSEA (Figure 2A), and 10 mM MTSES (B). 
The means and SEM are shown. The number 
of independent experiments for each mutant 
is shown next to the bars. Closed bars indicate 
mutants for which inhibition was significantly 
different (p < .05) than Cl18S by one-way 
ANOVA. In C 118S, Cys-126 is the only cysteine 
present in M3, but it is insensitive to the MTS 
reagents. Cys-126 is thus present in all the mu- 
tants. WT, wild type; asterisk, no detectable 
binding. 
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111, Va1-115, Cys-118, Ser-121, Ile-122, Leu-125, and 
Ser-129. 
Mechanism of the Inhibition of Binding by Reaction 
with MTS Reagents 
The inhibitory effects of the addition of -SCH2CH2X to the 
cysteine could be due to steric block, electrostatic repul- 
sion, conformational changes, or a combination of these. 
Given that the reaction of MTSEA with cysteine generates 
a positively charged side chain resembling the lysine side 
chain, and that YM-09151-2 is also positively charged, 
electrostatic repulsion must contribute to the inhibition of 
binding. Nevertheless, there are three lines of evidence 
which suggest that some of the engineered cysteines are 
close to bound YM-09151-2 and that steric overlap also 
contributes to the inhibition: first, dithiopyridine, which 
adds the neutralthiopyridine toCys-118, inhibited the bind- 
ing of [3H]YM-09151-2 (unpublished data). Second, the 
reaction of MTSEA with Cys-118, which blocked [3H]YM- 
09151-2 binding, had only a small effect on the binding 
of the competitive antagonist [3H]N-methylspiperone; the 
reaction of the slightly larger MTSET with Cys-118, how- 
ever, blocked the binding of both antagonists (data not 
shown). Thus, small changes in the size of the added 
-SCH2CH2X had a large effect on the resulting inhibition. 
Therefore, given that YM-09151-2 and N-methylspiperone 
bind to overlapping sites, Cys-118 is close to these sites. 
Third, the protection of the 10 residues in the binding-site 
crevice bythe antagonist sulpiride, which is similar chemi- 
cally to YM-09151-2, is most simply explained by their 
proximity to the sulpiride- and YM-09151-2-binding site. 
Nevertheless, not every one of these residues need con- 
tact sulpiride; sulpiride could protect residues deeper in 
the crevice by binding above them and blocking the pas- 
sage of MTSEA from the extracellular medium to the cyto- 
plasmic end of the crevice. In addition, we cannot rule out 
indirect effects through propagated structural changes for 
either inhibition by the MTS reagents or protection by 
sulpiride. 
It is clear for D108C that there is an electrostatic ompo- 
nent to the alteration of binding due to the addition of 
-SCH2CH2X. Replacement of the aspartate by cysteine in 
D108C decreased affinity 4-fold (Table 1); modification by 
MTSES, which restores negative charge to the side chain, 
increased the affinity 2-fold, increasing binding (Figure 
5B). In contrast, modification by the positively charged 
MTSEA (Figures 2A and 2B) and MTSET (Figure 5A) inhib- 
ited binding. 
The Secondary Structure of 
the Binding-Site Crevice 
To infer a secondary structure, we must assume that, if 
binding to a mutant is not affected by the MTS reagents, 
then no reaction has occurred and that the side chain at 
this position is not exposed in the binding-site crevice. 
Because the exposed residues from Phe-110 to Ser-129 
are contained within an arc of 140 ° in a helical wheel 
representation of M3 (Figure 4B), these residues would 
be located on one side of an ~ helix (Figure 4A). Unless, 
at the extracellular end of M3, an arc of 300 ° is exposed 
and protected by sulpiride, Asp-108 and Ile-109 are not 
likely to be in an a-helical conformation and may be part 
of the loop between M2 and M3. An R-helical conformation 
of M3 is consistent with the accepted structures of rhodop- 
sin (Baldwin, 1993; Schertler et al., 1993) and bacteriorho- 
dopsin (Henderson et al., 1990). 
Asp-114 is the only residue in M3 of the D2 receptor, 
and of homologous biogenic amine receptors, previously 
identified as contributing to binding. Asp-114 likely plays 
an important role in the binding of the positively charged 
ammonium of catecholamines and competitive antago- 
nists of these ligands (Mansour et al., 1992; Strader et 
al., 1994). Although we could not determine directly the 
accessibility of Asp-114, given the pattern of accessibility 
of its neighbors, it almost certainly faces the binding-site 
crevice. In a helical-net representation, the most reactive 
cysteines, Cys-118 and those substituted for Val-111 and 
Va1-115, cluster around Asp-114 (Figure 4A). 
In addition to the conserved Asp-114, the exposed Val- 
115 aligns with muscarinic receptor Tyr-148, implicated 
in the binding of agonists (Wess et al., 1991), and the 
exposed Phe-110 aligns with rhodopsin Glu-113, thought 
to provide the counterion for the retinal Lys-296 protonated 
Schiff base (Sakmar et al., 1989; Nathans, 1990; Zhukov- 
sky and Oprian, 1990). In the different G protein-coupled 
receptors, aligned residues may be exposed in the bind- 
ing-site crevices and yet make more or less crucial contri- 
butions to binding in the different receptors. In the D2 
receptor, except for Asp-114, none of the specific side 
chains in M3 are indispensable for the binding of the antag- 
onist [3H]YM-09151-2, because the mutation of the resi- 
dues to cysteine decreased the affinity at most 5-fold. 
V115C had the lowest affinity, and the rate of reaction of 
MTSEA was the greatest in this mutant, consistent with 
the Va1-115 side chain being close to bound ligand. Con- 
clusions about the surface accessibility and proximity to 
bound ligand of a side chain could not be made simply 
on the basis of the effect of mutagenesis on the binding 
of YM-09151-2; e.g., although Leu-113 is not exposed in 
the binding-site crevice (Figure 4), the mutant L113C had 
an affinity for YM-09151-2 nearly 4-fold lower than did 
Cl18S. 
The residues exposed in the binding-site crevice span 
M3 from the extracellular end to the intracellular end. 
MTSEA reacted with cysteines substituted for Leu-125 and 
Ser-129, putatively at the cytoplasmic end of M3 (Probst et 
al., 1992; Baldwin, 1993). The rate constant of the reaction 
with these residues was roughly one-half that seen at the 
most extracellular end of M3, suggesting that access deep 
in the crevice is not dramatically impaired. It is possible 
that the binding-site crevice extends to the cytoplasmic 
end of M3, and, perhaps, provides a water-accessible path 
from the extracellular medium to the cytoplasm. 
Electrostatic Potential in the Binding-Site Crevice 
MTSES did not react with cysteines substituted for resi- 
dues more cytoplasmic than Val-11 t (Figure 5B), This is 
consistent with a negative electrostatic potential in the 
binding-site crevice, owing in part to the negative charge 
of Asp-114 (Javitch et al., 1994). However, MTSES reacted 
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with the mutants D108C, I109C, F110C, and V111C (Fig- 
ure 5B). At 1109C, F110C, and V111C, 10 mM MTSES 
inhibited binding nearly as much as 1 mM MTSET (Figures 
5A and 5B). Because 1 mM MTSET and 10 mM MTSES 
are equireactive with simple thiols in solution (Stauffer and 
Karlin, 1994), the rates of reaction of MTSET and MTSES 
with the residues located near the extracellular end of M3 
are similar; this indicates that the electrostatic potential 
near these residues is not as negative as it is below 
Val-111. 
Comparison of Reactions with MTSEA and MTSET 
When adjusted for the rate constants for their reactions 
with simple thiols in solution (Stauffer and Karlin, 1994), 
the reaction of MTSEA with cysteines in the binding-site 
crevice is accelerated approximately 10-fold relative to 
that of MTSET (Figures 2A and 2B; Figure 5A). MTSEA, 
like dopamine, contains an ethylammonium group, and it 
could be the affin ity of this group for the dopamine-binding 
site that accelerates the reaction of MTSEA, especially 
with the most reactive mutants, V111C and Vl15C, and 
with wild-type receptor containing Cys-118. MTSEA is also 
slightly smaller than MTSET. This difference probably ac- 
counts for the susceptibility of 1122C to MTSEA but not 
to MTSET. 
Binding-Site Specificity 
The known crucial residues in catecholamine receptors 
are highly conserved and therefore not likely to account 
for the differences in binding specificities among these 
receptors. These differences in specificity are particularly 
marked for antagonists and synthetic agonists and occur 
eve n among receptor subtypes. For example, the antago- 
nist raclopride has a 20-fold higher affinity for the D2 than 
for the D4 receptor, and the antagonist clozapine has a 
15-fold higher affinity for the D4 than for the D2 receptor 
(Van Tol et al., 1991). The residues that determine these 
differences in specificity are likely to be among those iden- 
tified by SCAM as exposed in the binding-site crevice. 
Thus, while 8 residues in M3 differ between the dopamine 
D2 and D4 receptors (Grandy et al., 1989; Van Tol et al., 
1991 ; Probst et al., 1992), only 3 of these, Ile-109, Phe-110, 
and Val-111, face the binding-site crevice in the D2 recep- 
tor. If M3 contributes to the pharmacological differences 
between these receptors, 1 or more of these 3 residues, 
or their counterparts in the D4 receptor, might directly in- 
teract with these ligands. Finally, the residues identified 
by SCAM as facing the binding-site crevice are novel tar- 
gets for new therapeutic agents. 
Experimental Procedures 
Site-Directed Mutagenesis 
The coding region of the D2 receptor cDNA was subcloned at the 
EcoRI site into pcDNA1/Amp (Invitrogen), yielding the plasmid pcD2, 
and into pAlter-1 (Promega), yielding pAIterD2. Oligonucleotides were 
synthesized to generate the appropriate cysteine mutation and to intro- 
duce simultaneously a silent restriction site. The Altered Sites Mu- 
tagenesis System (Promega) was used to introduce the desired 
mutation. Mutations were identified using restriction mapping and con- 
firmed by DNA sequencing. An appropriate cassette containing the 
mutation was sequenced in its entirety and subcloned into pcD2 to 
generate the appropriate mutant expression plasmid. Mutants are 
named as wild-type residue-residue number-mutant residue, with the 
residues given in the single-letter code. 
Transient Transfection 
HEK 293 cells were grown in DMEM/F12 (1:1) containing 3.15 g/I 
glucose (Specialty Media) in 10% bovine calf serum (Hyclone) at 37°C 
and 5°/0 CO2. HEK 293 cells at 60%-80% confluence in 35 mm dishes 
were cotransfected with 0.67 p.g of pcD2 or mutant pcD2 and 0.13 ~g 
of pRSVTag using 5 I11 of lipofectamine (GIBCO) and 1 ml of OPTIMEM 
(GIBCO). At 5 hr after transfection, the plates were diluted with 1 ml 
of media containing 20% bovine calf serum; 24 hr after transfection, 
the media was changed; 48 hr after transfection, cells were washed 
with PBS (8.1 mM NaH2PO,, 1.5 mM KH2PO4, 138 mM NaCI, 2.7 mM 
KCI [pH 7.2]), briefly treated with PBS containing 5 mM EDTA, and 
then dissociated in PBS. Cells were pelleted at 1000 x g for 5 rain 
at 4°C and resuspended for binding or treatment with MTS reagents. 
[3H]YM-09151-2 Binding 
For saturation binding, whole cells were resuspended in 450 ~.1 of PBS 
containing 0.9 mM CaCI2, 0.5 mM MgCI2, and 0.5 mM EDTA at pH 
7.4 (buffer A). Cells were then diluted 50-fold with buffer A. Binding 
of [3H]YM-09151-2 (Dupont/NEN) was determined by a modification of 
reported procedures (Niznik et al., 1985; Javitch et al., 1994). Triplicate 
borosilicate tubes contained six different concentrations of [3H]YM- 
09151-2 between 5 and 400 pM in buffer A with 900 I11 of cell suspen- 
sion in a final volume of 2 ml. The mixture was incubated at room 
temperature for 60 rain and then filtered using a Brandel cell harvester 
through Whatman 934AH glass fiber filters (Brandel). The filter was 
washed twice with 5 ml of 10 mM Tris-HCI, 120 mM NaCI (pH 7.4) at 
room temperature. Specific [3H]YM-09151-2 binding was defined as 
total binding less nonspecific binding in the presence of 30 p.M sulpiride 
(Research Biochemicals). 
Reactions with MTS Reagents 
For treatment with MTS reagents, whole cells were resuspended in 
450 p.I of buffer B (25 mM HEPES, 140 mM NaCI, 5.4 mM KCI, 1 mM 
EDTA, 0.006% bovine serum albumin [pH 7.4]). Aliquots (50 ~1) of cell 
suspension were incubated with MTS reagents at the stated concentra- 
tions at room temperature for 2 rain. Cell suspensions were then diluted 
60-fold, and 900 p.I aliquots were used to assay for [3H]YM-09151-2 
(100 pM) binding as described above, using buffer B for binding buffer. 
Equivalent results were obtained with buffer A and buffer B for both 
binding and MTS treatment. The fractional inhibition was calculated 
as 1 - [(specific binding after MTS reagent)/(specific binding without 
reagent)[. We used the SPSS for Windows (SPSS, Inc.) statistical 
software to analyze the effects of the MTS reagents by one-way 
ANOVA according to Student-Newman-Keuls criteria (p < .05). 
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